OncLive discusses the Breast Cancer Index as a tool to guide shared decision-making on the duration of extended adjuvant hormonal therapy in HR-positive early-stage breast cancer, focusing on clinical relevance for long-term management.
Dr Diab on the Clinical Relevance of the Breast Cancer Index in HR+ Early-Stage Disease.
foundational tool for guiding shared decision-making
duration of extended adjuvant hormonal therapy
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new authority voices, debates, and emerging ideas.
← Back to Healthcare